Cyntec to market AEterna Zentaris' Zoptrex in Taiwan and Southeast Asia

6 July 2016

Canada’s AEterna Zentaris (TSX: AEZ) and Orient EuroPharma (OEP) have signed an exclusive license agreement between the company and Cyntec, an affiliate of OEP for its lead anti-cancer compound, Zoptrex (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Taiwan and nine countries in Southeast Asia.

Zoptrex, a novel synthetic peptide carrier linked to doxorubicin as a New Chemical Entity (NCE), is currently in a fully-enrolled Phase III clinical trial in endometrial cancer. The Company expects to complete the Phase III clinical trial in the third quarter of 2016 and, if the results of the trial warrant doing so, to file a New Drug Application for Zoptrex in the first half of 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK